Overview
Brief Summary:
The main purpose of the study is to learn about how well Trumenba vaccine shot works against gonorrhea infection.
This study looks at data records from a database in the United States.
This study includes patient's data from the database who:
- Are 15-30 years old.
- Have received at least one dose of Trumenba and a MenACWY vaccine or who have received only MenACWY vaccine.
- Have enough months of data in the database.
This data has already been collected in the past and is being studied between April and June of 2023.
Description
This study is a retrospective cohort study including individuals registered and available in the PharMetrics Plus database from 01 Jan 2016 to 31 Dec 2022 In order to estimate the effect of Trumenba vaccination, the cumulative incidence rate over time of the defined disease of interest among Trumenba + MenACWY vaccines will be compared to that among MenACWY vaccinees. Stratified analysis will be made by age groups, gender and state of residence
Eligibility
Inclusion Criteria:
- Individuals of 15-30 years old registered in the PharMetrics Plus system
- Individuals having the index vaccination event at the age of 15-30 in 2016-2021
- Individual with continuous enrollment for 60 months during 2016-2020 to capture complete medical claims history
Exclusion Criteria:
- Individuals having any dose of Bexsero at any time during the study period and prior to the study
- Individuals with incomplete information on variables to be collected.